4.4 Article

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program

Related references

Note: Only part of the references are listed.
Review Oncology

IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer

Mads Gyrd-Hansen et al.

NATURE REVIEWS CANCER (2010)

Article Oncology

Molecular characterization of the pediatric preclinical testing panel

Geoffrey Neale et al.

CLINICAL CANCER RESEARCH (2008)

Article Biochemistry & Molecular Biology

c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α (TNFα)-induced NF-κB activation

Eugene Varfolomeev et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2008)

Article Biochemistry & Molecular Biology

cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination

Mathieu J. M. Bertrand et al.

MOLECULAR CELL (2008)

Article Oncology

Initial testing of VNP40101M (Cloretazine®) by the pediatric preclinical testing program

Stephen T. Keir et al.

PEDIATRIC BLOOD & CANCER (2008)

Article Multidisciplinary Sciences

Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation

D. J. Mahoney et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Article Biochemistry & Molecular Biology

Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family

Brendan P. Eckelman et al.

EMBO REPORTS (2006)

Article Chemistry, Medicinal

Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer

TK Oost et al.

JOURNAL OF MEDICINAL CHEMISTRY (2004)

Article Multidisciplinary Sciences

Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

ZH Liu et al.

NATURE (2000)

Article Multidisciplinary Sciences

Structural and biochemical basis of apoptotic activation by Smac/DIABLO

JJ Chai et al.

NATURE (2000)